Andrea Williams, chief executive of Christian Concern, said: Whatever is announced by the Government in May, the problems remain: the definitions are inadequate, human rights will be breached and there is no evidence that a ban will help anyone.
In such a scenario we will face no alternative but to pursue legal action against any proposed legislation in this area.
Ms Williams added: The Government is being strong-armed by manipulative campaigns rather than following its own research that further legislation is not needed.
The fear of upsetting privileged lobbyists runs so deep the Prime Minister capitulated within hours.
No one has produced any evidence of what LGBT activists call coercive conversion therapy. What the activists describe would already be illegal.
The Governments proposals would only stop people seeking the change they want to see in their lives. That is a basic freedom which the Government should not try to take away.
Last week the Government was forced to cancel its first ever LGBT+ conference after more than 100 activist groups quit over its U-turn on conversion therapy.
As a result of the Government reiterating its commitment to excluding transgender people from the conversion therapy ban, a number of leading charities and organisations pulled out of the inaugural and international event, called Safe To Be Me.
It was set to take place in London from June 29 to July 1, coinciding with the 50th anniversary of the first official London Pride marches.
Christian Concern has threatened, if the Government does go ahead with any of its proposals as part of the Queens Speech on May 10, to bring legal proceedings on grounds of infringement upon rights of religious freedom enshrined in the European Convention on Human Rights.
A spokesman for Stonewall, one of the groups which pulled out of the Governments now collapsed Safe To Be Me conference, said: From the British Medical Association and NHS England to the UK Council for Psychotherapy and the Royal Colleges of GPs and Psychiatrists, medical and psychiatric expertise is in agreement: conversion practices do not work, can cause lifelong trauma and must be banned.
With half of conversion practices happening in religious settings, LGBTQ+ people of faith make up one of the largest groups of victims. Thats why were heartened that numerous religious leaders, including the former Archbishop of Canterbury, Rowan Williams, recently wrote to the Prime Minister in support of a ban.
We must continue to look to religious leaders who, rather than turn a blind eye to abuse, wish to address the harms done to other people who deeply hold and value their religious beliefs and community.
Read the original here:
Christian group prepares legal challenge over conversion therapy ban - The Telegraph
- Eye exercises for vertigo: Exercises to try at home - Medical News Today - January 6th, 2023
- EMDR therapy: Everything you need to know - Medical News Today - December 28th, 2022
- Eye floaters: What causes them, and what can you do? - Medical News Today - December 28th, 2022
- Eye care professional - Wikipedia - December 28th, 2022
- New gene therapy to treat rare eye disease now available in Alberta ... - December 28th, 2022
- Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol - PR Newswire - August 11th, 2022
- New research digs into the genetic drivers of heart failure, with an eye to precision treatments - STAT - August 11th, 2022
- Gamma Probe Device Market Trends, On-going Demand, Opportunities, Segmentation, and Forecast till 2031 - BioSpace - August 11th, 2022
- Babies born exposed to opioids and drugs need our support - GoErie.com - August 3rd, 2022
- Centrifuge Market: Increasing Prevalence of Infectious Diseases to Drive the Market - BioSpace - August 3rd, 2022
- Myopic macular degeneration: What it is, and more - Medical News Today - July 17th, 2022
- Roche Wraps Week with a Bang, Touting Long-Term Breast Cancer, AMD Data - BioSpace - July 17th, 2022
- EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment... - July 17th, 2022
- What Are These Things Floating in Front of My Eyes? - The Epoch Times - July 17th, 2022
- Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022... - July 17th, 2022
- Retinoblastoma among children: Early detection and treatment are vital - The Financial Express - May 20th, 2022
- Perceive Biotherapeutics Appoints Anne E. Fung MD, as Chief Medical Officer to Drive Transformational Clinical Programs - PR Newswire - May 20th, 2022
- Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101 -... - May 20th, 2022
- How the Pandemic is Taking a Toll on Rhode Island's Front-Line Health Care Workers - Rhode Island Monthly - May 20th, 2022
- Myrtelle Enters into a Worldwide Exclusive License Agreement with Rescue Hearing to Develop and Commercialize Gene Therapy for the Treatment of... - May 20th, 2022
- Capsida, Adverum, Instil and Metagenomi Showcase Therapies at ASGCT - BioSpace - May 20th, 2022
- GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of... - May 20th, 2022
- How Diabetes can be a driver for High blood pressure and eventually leads to Hypertension - APN News - May 20th, 2022
- Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative - Yahoo Finance - April 11th, 2022
- PFE: 5 Global Healthcare Stocks to Buy as BofA Warns of a - StockNews.com - April 11th, 2022
- Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the... - April 11th, 2022